A pharmacokinetic model for L-carnitine in patients receiving haemodialysis

British Journal of Clinical Pharmacology

Volumn 64, Issue 3, 2007, Pages 335-345

  Fornasini, Gianfranco ^a   Upton, Richard N ^b,d   Evans, Allan M ^c  

^a Sigma Tau Pharmaceuticals Inc   (United States)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Haemodialysis; L carnitine; Modelling; Muscle; Pharmacokinetics

Indexed keywords

CARNITINE;

ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; EXPERIMENTAL STUDY; FEMALE; HEMODIALYSIS; HUMAN; MALE; MUSCLE LEVEL; PRIORITY JOURNAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TURNOVER TIME;

AUSTRALIA; CARNITINE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; RENAL DIALYSIS;

EID: 34548013483     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02926.x     Document Type: Article

References (18)

1. Bremer J. Carnitine - metabolism and functions. Physiol Rev 1983 63 : 1420 80.
2. Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals. Biochem J 2000 361 : 417 29.
3. Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci 2004 1033 : 30 41.
4. Evans AM, Fornasini G. Pharmacokinetics of L-carnitine. Clin Pharmacokinet 2003 42 : 941 67.
5. Ahmad S. L-carnitine in dialysis patients. Semin Dialysis 2001 14 : 209 17.
6. Debska-Slizien A, Kawecka A, Wojnarowski K, Prajs J, Malgorzewicz S, Kunicka D, Zdrojewski Z, Lysiak-Szydlowska W, Lipinski J, Rutkowski B. Correlation between plasma carnitine, muscle carnitine and glycogen levels in maintenance hemodialysis patients. Int J Artif Organs 2000 23 : 90 6.
7. Hiatt WR, Koziol BJ, Shapiro JI, Brass EP. Carnitine metabolism during exercise in patients on chronic hemodialysis. Kidney Int 1992 41 : 1613 9.
8. Evans AM, Faull R, Fornasini G, Lemanowicz E, Longo A, Pace S, Nation RL. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long term dialysis. Clin Pharm Ther 2000 68 : 238 49.
9. Glöggler A, Bulla M, Fürst P. Kinetics of intravenously administered carnitine in haemodialysed children. J Pharmaceut Biomed Anal 1990 3 : 411 4.
10. Harper P, Elwin C-E, Cederblad G. Pharmacokinetics of bolus intravenous and oral doses of L-carnitine in healthy subjects. Eur J Clin Pharmacol 1988 35 : 69 75.
11. Rebouche CJ, Engel AG. Kinetic compartmental analysis of carnitine metabolism in the human carnitine deficiency syndromes. Evidence for alterations in tissue carnitine transport. J Clin Invest 1984 73 : 857 67.
12. Segre G, Bianchi E, Corsi M, D'Iddio S, Ghirardi O, Maccari F. Plasma and urine pharmacokinetics of free and of short-chain carnitine after administration of carnitine in man. Arzneimittelforschung 1988 38 : 1830 4.
13. Uematsu T, Itaya T, Nishimoto M, Takiguchi Y, Mizuno A, Nakashima M, Yoshinobu K, Hasebe T. Pharmacokinetics and safety of L-carnitine infused i.v. in healthy subjects. Eur J Clin Pharmacol 1988 34 : 213 6.
14. Brass EP. Pharmacokinetic considerations for the therapeutic use of carnitine in hemodialysis patients. Clin Ther 1995 17 : 176 85.
15. Evans AM, Faull RJ, Nation RL, Prasad S, Elias T, Reuter SE, Fornasini G. Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. Kidney Int 2004 66 : 1527 34.
16. Mitchell M. Carnitine metabolism in human subjects II. Values of carnitine in biological fluids and tissues of 'normal' subjects. Am J Clin Nutr 1978 31 : 481 91.
17. Angelini C, Vergani L, Martinuzzi A. Clinical and biochemical aspects of carnitine deficiency and insufficiency: transport defects and inborn errors of beta-oxidation. Crit Rev Clin Lab Sci 1992 29 : 217 42.
18. Martinuzzi A, Vergani L, Rosa M, Angelini C. L-carnitine uptake in differentiating human cultured muscle. Biochimica Biophysica Acta 1991 1095 : 217 22.